We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.05%
5 Year Est. Return
+670.56%
10 Year Est. Return
AUM
$1.05B
AUM Growth
+$9.85M
Cap. Flow
+$95.1M
Cap. Flow %
9.1%
Top 10 Hldgs %
50%
Holding
874
New
223
Increased
214
Reduced
73
Closed
220

Sector Composition

Rank Sector Weight
1 Healthcare 34.11%
2 Financials 8.03%
3 Materials 6.97%
4 Technology 3.58%
5 Industrials 3.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FRGE.WS
851
DELISTED
Forge Global Holdings, Inc. Warrants, each whole warrant exercisable for one share of Common Stock a
FRGE.WS
-16,499
Closed -$1K
ATVI
852
PUT
DELISTED
Activision Blizzard
ATVI
-20,600
Closed -$92K
KACLU
853
DELISTED
Kairous Acquisition Corp. Limited Unit
KACLU
-39,900
Closed -$400K
PICC
854
DELISTED
Pivotal Investment Corporation III
PICC
-100,000
Closed -$981K
VG
855
DELISTED
Vonage Holdings Corporation
VG
-29,900
Closed -$563K
ENV
856
CALL
DELISTED
ENVESTNET, INC.
ENV
-28,900
Closed -$77K
ENV
857
PUT
DELISTED
ENVESTNET, INC.
ENV
-2,500
Closed -$3K

Similar funds

Cowen and Company's Q3 2022 Portfolio in Review

As of Q3 2022, Cowen and Company held 874 positions worth $1.05B, up 0.95% from $1.04B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cowen and Company deployed $95.1M of net new capital in Q3 2022, opening 223 new positions and adding to 214 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 726,608 shares worth $20.8M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Relmada Therapeutics, an estimated $23.6M trimmed.

  • Cowen and Company's largest Q3 2022 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 726,608 shares worth $20.8M.
  • Cowen and Company added most to ARK Innovation ETF in Q3 2022, an estimated $41.6M increase.
  • Cowen and Company's biggest Q3 2022 reduction was Relmada Therapeutics, cutting an estimated $23.6M.
  • Cowen and Company fully exited Pershing Square Tontine Holdings, Ltd. in Q3 2022, selling an estimated $19M.
  • Cowen and Company's ten largest holdings make up 50% of its $1.05B portfolio in Q3 2022.
  • Cowen and Company opened 223 new positions and closed 220 in Q3 2022.
  • Cowen and Company's portfolio value rose 0.95% quarter-over-quarter to $1.05B.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.